Last 10,550 KRW
Change Today 0.00 / 0.00%
Volume 23.7K
068760 On Other Exchanges
Symbol
Exchange
KOSDAQ
As of 12:29 AM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

celltrion pharm inc (068760) Snapshot

Open
10,450
Previous Close
10,550
Day High
10,700
Day Low
10,450
52 Week High
08/1/13 - 18,300
52 Week Low
12/20/13 - 9,950
Market Cap
151.9B
Average Volume 10 Days
61.9K
EPS TTM
183.00
Shares Outstanding
14.4M
EX-Date
12/29/09
P/E TM
57.7x
Dividend
--
Dividend Yield
--
Current Stock Chart for CELLTRION PHARM INC (068760)

Related News

No related news articles were found.

celltrion pharm inc (068760) Related Businessweek News

No Related Businessweek News Found

celltrion pharm inc (068760) Details

Celltrion Pharm Inc., a pharmaceutical company, produces and sells biosimilars and over-the-counter drugs in South Korea. It offers hepatotonic, anti-inflammatory, antihistamine, respiratory apparatus, circulary system, digestive and stomachic, hormone/metabolic disease, antibiotics/antimycotic, nutrientia and tonic, immunology, oncology, and other drugs. The company also exports its products to South-East Asian countries, such as China, the Philippines, Vietnam, and Kazakhstan. It serves approximately 3800 customers, including university hospitals and general pharmacies. The company was founded in 1976 and is headquartered in Seoul, South Korea.

Founded in 1976

celltrion pharm inc (068760) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

celltrion pharm inc (068760) Key Developments

Celltrion Pharm Inc., Annual General Meeting, Mar 28, 2014

Celltrion Pharm Inc., Annual General Meeting, Mar 28, 2014., at 09:00 Korea Standard Time. Location: 706-1, Yeoksam-dong, Gangnam-gu, Seoul Tower, 6th Floor Kite. Agenda: To approve the Financial Statement; to approve the articles of incorporation to change some; to approve election of Directors; to approve director remuneration; and to approve stock option grants.

Celltrion In Talks For Controlling Stake Sale

Celltrion Pharm Inc. (KOSDAQ:A068760) said it is in talks with undisclosed potential buyers over its controlling stake sale. Celltrion said in a regulatory filing that Celltrion’s largest shareholder signed a contract with JP Morgan for the management of the planned stake sale and concrete talks are underway with potential buyers.

Celltrion Appoints Jpmorgan As Advisor On Possible Sale By Seo Jung-Jin

Celltrion, Inc. announced hiring JPMorgan Chase & Co. as advisor on the possible sale stake sale by Seo Jung-Jin, Founder of Celltrion in Celltrion, CelltrionHealthcare, Co., Ltd and Celltrion Pharm Inc. Celltrion is yet to figure out the number and the value of the deals required for the asset sales. Seo Jung-Jin said on April 16, 2013 that he will take his hands off the business he created in 2002, blaming speculative short selling against Celltrion. "I decided to sell my company to a multinational pharmaceutical company to make it a strong one that can guard off continuous suspicions and attacks by speculative investors," Seo Jung-Jin said in a statement.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
068760:KS 10,550.00 KRW 0.00

068760 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 068760.
View Industry Companies
 

Industry Analysis

068760

Industry Average

Valuation 068760 Industry Range
Price/Earnings 100.0x
Price/Sales 3.0x
Price/Book 0.9x
Price/Cash Flow 73.2x
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELLTRION PHARM INC, please visit www.celltrionph.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.